Breast Cancer New Indication: Adjuvant Ribociclib and Endocrine Therapy in Breast Cancer Ulas D. Bayraktar, MD 2023-06-24
Breast Cancer New Indication: Randomized Phase II Trial of Endocrine Therapy With or Without Ribociclib After Progression on Cyclin-Dependent Kinase 4/6 Inhibition in Hormone Receptor–Positive, Human Epidermal Growth Factor Receptor 2–Negative Metastatic Breast Cancer (MBC) Ulas D. Bayraktar, MD 2023-06-07
